|
|
|
|
|
27.07.26 - 12:51
|
Novo Nordisk A/S - share repurchase programme (GlobeNewswire EN)
|
|
|
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026....
|
|
|
|
|
27.07.26 - 07:06
|
Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma) (Cision)
|
|
|
Copenhagen, 27 July 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces a protocol amendment to the ongoing Phase I clinical trial evaluating uTREAT® in patients with glioblastoma. The amendment has been submitted to the relevant regulatory authorities and is pending approval
The proposed amendment is intended to optimize the clinical study design and broaden the information obtained to design next phase studies.
The key proposed changes include:
· Administration of uTREAT® without blood-brain barrier disruption through mannitol for newly enrolled patients....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.07.26 - 12:00
|
FDA grants fast track designation for Lundbeck′s Lu AH69593 (PBR)
|
|
|
Lu AH69593 is an oral, small-molecule agonist of the orexin 2 receptor (OX2R). The compound is currently being studied in a Phase Ib clinical trial focused on patients
The post FDA grants fast track designation for Lundbeck's Lu AH69593 appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
24.07.26 - 08:36
|
Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu (Cision)
|
|
|
·
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the Paediatric Use Marketing Authorisation (PUMA) application for CT001/KemSu (intranasal sufentanil/ketamine).
·
Proveca intends to request a re-examination of the CHMP opinion in accordance with EMA procedures.
·
Proveca and Cessatech remain committed to working closely with the EMA throughout the re-examination process.
·
CT001/KemSu continues to represent an important potential treatment option for children with moderate to severe acute pain...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
